FDA starts speedy review of Enhertu in lung cancer

FDA starts speedy review of Enhertu in lung cancer

Source: 
Pharmaforum
snippet: 

AstraZeneca and Daiichi Sankyo should only have to wait for six months to hear from the FDA if it will approve their HER2 drug Enhertu for non-small cell lung cancer (NSCLC) and add to its current uses in breast and gastric cancer.